Will second time be the charm for Macrilen? AEZS closed Tuesday's trading at $1.02, down 2.86%. In after-hours, the stock zoomed 47.06% to $1.50. Aldeyra Therapeutics Inc. (ALDX) announced that the last patient has completed …
A year ago, they were trading at $3.25. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AEZS at https://www.zacks.com/ap/AEZS
Approval of macimorelin might have a modest effect on the stock: learning from Synergy Pharmaceuticals Unfortunately, following any approval, uncertainty may just as soon creep in over how AEZS is going to fund the launch and marketing …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AEZS at https://www.zacks.com/ap/AEZS Keywords: Aeterna Zentaris, …